Enhancement of Treatment Completion for Latent Tuberculosis Infection With 4 Months of Rifampin*
|
|
- Sydney Rich
- 6 years ago
- Views:
Transcription
1 CHEST Enhancement of Treatment Completion for Latent Tuberculosis Infection With 4 Months of Rifampin* Alfred Lardizabal, MD; Marian Passannante, PhD; Faysal Kojakali, MPH; Christopher Hayden, BA; and Lee B. Reichman, MD, MPH, FCCP Original Research TUBERCULOSIS Background: Isoniazid is the standard medication used to treat latent tuberculosis infection (LTBI). The lengthy treatment with isoniazid, its perceived hepatotoxicity, and the increasing influx of foreign-born persons from countries with a higher prevalence of isoniazid resistance have compromised this regimen. In 2000, the Centers for Disease Control and Prevention guidelines recommended 4 months of rifampin (4R) as an acceptable alternative regimen to 9 months of isoniazid (9H). In a county chest clinic in northern New Jersey, a self-administered 9H regimen for patients with LTBI was generally prescribed until the year After recognizing poor completion rates, LTBI treatment was shifted predominantly to the alternative 4R regimen. Methods: Medical records of patients placed on LTBI treatment during 2000 (predominantly a 9H regimen) and 2003 (predominantly a 4R regimen) were reviewed. A total of 474 patients were included in the study. 2, Fishers exact, two-sample t, and Wilcoxon rank-sum tests and logistic regression were used to analyze the data. The main outcome variable was treatment completion. Results: A total of 80.5% of patients receiving 4R and 53.1% receiving 9H completed treatment (p < ); 34.7% of patients receiving 9H were unavailable for follow-up, compared to 12.6% receiving 4R (p <0.0001). Fewer drug reactions were observed in the group receiving 4R compared to the group receiving 9H (3.1% vs 5.8%), although this was not statistically significant. Logistic regression analysis identified treatment regimen as a significant predictor for treatment completion (odds ratio [OR], 5.1; 95% confidence interval [CI], 3.3 to 8.1). Employment was negatively associated with treatment completion in the same model (OR, 0.54; 95% CI, 0.34 to 0.94). Conclusions: Patients receiving 4R were significantly more likely to complete therapy than those receiving 9H. (CHEST 2006; 130: ) Key words: isoniazid; latent tuberculosis infection treatment; rifampin Abbreviations: ATS American Thoracic Society; CDC Centers of Disease Control and Prevention; CI confidence interval; IDSA Infectious Disease Society of America; LTBI latent tuberculosis infection; OR odds ratio; TB tuberculosis; 2RZ 2 months of rifampin and pyrazinamide; 4R 4 months of rifampin; 6H 6 months of isoniazid; 9H 9 months of isoniazid In 2004, a total of 14,511 cases of tuberculosis (TB) in the United States were reported to the Centers of Disease Control and Prevention (CDC), the lowest number since national reporting was instituted in *From the Global Tuberculosis Institute (Drs. Lardizabal and Reichman, and Mr. Hayden), School of Public Health (Mr. Kojakali), and the Department of Preventive Medicine and Community Health (Dr. Passannante), New Jersey Medical School, Newark, NJ. Drs. Lardizabal and Reichman are supported by the Regional Tuberculosis Training and Medical Consultation Center grant, Centers for Disease Control and Prevention While maintaining efforts to effectively manage TB cases and contacts, the CDC and the Institutes of Medicine have called for increased treat- None of the authors have any conflicts of interest to disclose. Manuscript received June 5, 2006; revision accepted September 2, Reproduction of this article is prohibited without written permission from the American College of Chest Physicians ( org/misc/reprints.shtml). Correspondence to: Alfred A. Lardizabal, MD, 225 Warren St, Second Floor, Newark, NJ 07103; lardizaa@umdnj.edu DOI: /chest Original Research
2 ment of high-risk persons with latent TB infection (LTBI) in order to accelerate the decline toward TB elimination. 2,3 Isoniazid has been the mainstay of LTBI treatment for 40 years. Unfortunately, the recommended lengthy (9 months) treatment with isonia- For editorial comment see page 1638 zid, 2 its reputation for toxicity, 4 and the increasing influx of foreign-born persons from countries with a high prevalence of isoniazid resistance 5 have compromised this regimen as an effective tool. Indeed, it has been recognized that many persons fail to complete the full course of LTBI treatment and remain at risk for TB. 2,6 Nationwide, even among infected contacts of sputum-positive TB patients in 2003, only 73% were placed on LTBI treatment; of these, only 59% completed therapy, resulting in a Dear Colleague letter from the CDC to call attention to this situation. 7 In the American Thoracic Society (ATS), CDC, and Infectious Disease Society of America (IDSA) official joint statement published in 2000, 6 months of isoniazid (6H), 4 months of rifampin (4R), and 2 months of rifampin and pyrazinamide (2RZ) were recommended as acceptable alternatives to the preferred 9 months of isoniazid (9H). 2 After the recommendations were published, because of severe toxicity and mortality among patients receiving 2RZ, recommendations were revised to indicate that this regimen should not generally be offered. 8 A clinical review of LTBI by Jasmer and colleagues 9 discusses the importance of diagnosing and treating LTBI; the authors mention that adverse reactions to rifampin are rare. However, the discussion about its role in the treatment of LTBI is brief. In an opinion piece, 10 we have offered several reasons for considering the expanded use of the 4R regimen in selected populations, based on the likelihood of high efficacy, its low toxicity, improved adherence, higher levels of isoniazid resistance among certain immigrant groups, as well as cost and site-specific considerations. In this present communication, we present our experience with this regimen, suggesting that it might go a long way in ameliorate the dismal LTBI adherence rates cited by the CDC. 7 Materials and Methods At a county chest clinic in central New Jersey, 9H was routinely prescribed for all LTBI patients until the year Due to poor adherence and completion rates, we began discussing other treatment options with patients, considering the length and complexity of the regimens, possible adverse effects, and potential drug interactions as recommended in the 2000 ATS/CDC/ IDSA guidelines. 2 Discussions of treatment options with each patient were made by the same physician (A.A.L.) with each patient, emphasizing 9H as the standard treatment and 4R as an acceptable alternative. During these discussions, we found that patients overwhelmingly requested the shorter regimen. By the end of 2002, 4R was the predominant regimen used to treat LTBI, unless contraindicated. Since the clinical staff and follow-up procedures have remained constant since 2000, we decided to review medical records of patients referred for LTBI evaluation during 2000 and 2003 in an effort to determine adherence with and acceptability of 4R compared with 9H. These two specific years were chosen because they were close enough not to present changes in staffing or clinic administration and far enough apart to represent distinct time periods when the vast majority of patients received only one of the treatments. Following published LTBI guidelines, 2 patients with LTBI during both study periods who had an increased risk for progression to disease were recommended to start treatment regardless of age. Baseline liver function tests were performed only if the patients had increased risk for hepatotoxicity (HIV infection, history of hepatitis or chronic liver disease, excess alcohol use, pregnancy). For both cohorts, per usual clinic practice, the nurses monitored each patient for adverse reactions and adherence during each face-to-face visit before the prescription refill each month. Adherence was judged by pill counts in returned bottles plus extensive discussions with the nurse and case manager to assess compliance and the fact that the patients continued to present themselves for the next dose. Blood work was ordered when the patient presented with complaints during these visits. This is an historical prospective review of patients treated for LTBI at a county chest clinic. An index file has always been maintained at the clinic of all patients referred for LTBI evaluation. For our study, patients referred during 2000 and 2003 were identified and their medical records were reviewed. Selected data items were abstracted onto a form, including demographic information, TB risk factors, and treatmentrelated variables such as adverse reactions and completion of therapy. For patients prescribed 9H, completion of therapy was defined as receiving enough medications to complete 270 doses within 12 months, although patients completing a minimum of 180 doses (6H) were also counted as completed. For patients prescribed 4R, patients completed therapy after receiving 120 doses within 6 months. Approval from the University of Medicine and Dentistry of New Jersey institutional review board including a waiver for informed consent was obtained prior to the initiation of this study. Data Analysis The collected data were entered into a password-protected computer and analyzed using the JMP statistical software package (SAS Institute; Cary, NC) to compare patient characteristics and treatment outcomes with each drug regimen. Significance tests were conducted at the 0.05 level. The main outcome measured was treatment completion. This was measured as a dichotomous outcome. The secondary study outcome was adverse drug reactions requiring cessation of treatment. 2 and Fisher exact tests were used for comparisons of categorical variables. Two-sample t tests and Wilcoxon rank-sum tests were used for comparison of continuous and nonnormally distributed data, respectively. Logistic regression was used to assess the independent contribution of independent variables on treatment completion. CHEST / 130 / 6/ DECEMBER,
3 Results Five hundred fifty-four patients referred for LTBI evaluation were identified. Patients with class 3 TB (current disease; n 4) and class 4 TB (old healed, untreated disease; n 16) were excluded from the study, as were 15 patients for whom LTBI treatment was not recommended. Patients with class 4 TB were excluded because these patients are started with multiple drugs until the diagnosis is confirmed with negative culture results. Of the 519 patients started on LTBI treatment, 22 who were prescribed specifically 6H were excluded so as not to confound the analysis comparing 9H and 4R, as were 23 patients who had moved to other areas (n 23) to continue treatment. The remaining 474 LTBI patients were included in the study. Table 1 characterizes our study population during the two time periods, 2000 (n 195) and 2003 (n 279). For both time periods, the majority of patients evaluated ( 90%) were foreign born, although the 2003 population was significantly more likely to be somewhat older, Hispanic, employed, and residing in the United States for 5 years. Approximately 99% of LTBI patients in the 2000 period were prescribed isoniazid, and 93% of LTBI patients in 2003 were prescribed rifampin. Table 1 Description of the Study Population, 2000 and 2003* Demographic and Risk Factors Year 2000 Year 2003 p Value Age group, yr (87.7) 177 (63.4) (6.7) 35 (12.5) (3.6) 42 (15.1) 45 4 (2.1) 25 (9.0) Gender Male 111 (56.9) 146 (52.3) 0.35 F Female 84 (43.1) 133 (47.7) Race White 22 (11.8) 18 (7.1) Black 13 (7.0) 22 (8.7) Hispanic 90 (48.1) 150 (59.5) Other 62 (33.2) 62 (24.6) Employment Employed 24 (12.3) 94 (33.7) F Unemployed 171 (87.7) 185 (66.3) Country of origin United States 12 (6.2) 28 (10.1) 0.14 F Foreign 183 (93.9) 249 (89.9) Lived in United States US born 12 (6.2) 28 (10.1) yr 161 (82.6) 182 (65.7) 5 yr 22 (11.3) 67 (24.2) Regimen 4R 1 (0.5) 260 (93.2) F 9H 194 (99.5) 19 (6.8) *Data are presented as No. (%). F Fisher exact test. Potential predictors of treatment completion are listed in Table 2. The number of risk factors variable was created by summing up the number of medical (ie, close contact, immunosuppression, skin test conversion, injection drug use, chronic medical conditions, silicosis, malnutrition, organ transplant history) and population risks (ie, prison/jail inmate or employee, long-term facility resident/employee, healthcare employee, homeless shelter resident/employee, foreign born in the United States 5 years, migrant worker) for development of TB identified for each patient, with a possible high score of 4 and a possible low score of 0. The total risk scores ranged from 0 to 3, with 76% having exactly one risk factor. Age was analyzed as a categorical variable with the two older groups (35 to 44 years and 45 years) separated to see if adverse drug reactions in these group might have an impact on treatment completion. The data in Table 2 illustrate that only two variables were significantly associated with treatment completion: treatment regimen and years in the United States; 80.5% of those receiving the 4R regimen completed treatment vs only 53.1% of those Table 2 Bivariate Analysis of Predictors of Treatment Completion* Demographic and Risk Factors Completed Treatment Not Completed p Value Age group, yr (70.1) 104 (29.9) (66.7) 16 (33.3) (55.1) 22 (44.9) (69.0) 9 (31.0) Gender Male 173 (67.3) 84 (32.7) 0.69 F Female 150 (69.1) 67 (30.9) Race White 27 (67.5) 13 (32.5) Black 26 (74.3) 9 (25.7) Hispanic 163 (67.9) 77 (32.1) Other 87 (70.2) 37 (29.8) Employment Employed 72 (61.0) 46 (39.0) 0.07 F Not employed 251 (70.5) 105 (29.5) Country of origin United States 25 (62.5) 15 (37.5) 0.48 F Foreign 298 (69.0) 134 (31.0) Length of time in the United States US born 25 (62.5) 15 (37.5) yr 52 (58.4) 37 (41.6) 5 yr 246 (71.7) 97 (28.3) TB risk factors W Regimen 4R 210 (80.5) 51 (19.5) F 9H 113 (53.15) 100 (47.0) *Data are presented as No. (% of row) unless otherwise indicated. W Wilcoxon signed rank. See Table 1 for expansion of abbreviation Original Research
4 receiving 9H (p ). Foreign-born persons in the United States for 5 years were significantly more likely to complete treatment (71.7%) than US-born persons (62.5%) or foreign-born persons in the United States for 5 years (58.3%) [p 0.039]. Fewer employed persons completed therapy (61.0%) compared to those who were unemployed (71.0%), but this was only marginally significant (children and students were counted as unemployed). Three independent variables were included in the logistic regression model (Table 3): treatment regimen, employment status, and time in the United States ( 5 years or 5 years). After controlling for the other independent variables, the logistic regression model identified a significant association between receiving the 4R regimen and treatment completion (p ), with an odds ratio (OR) of 5.1 (95% confidence interval [CI], 3.3 to 8.1). Employment was negatively associated with treatment completion (p 0.03). Time in the United States was entered into the model as dummy variables with US-born patients as the comparison group. Being in the United States for 5 years compared with US-born patients was marginally associated with treatment completion (p 0.09). Foreign-born patients who had lived in the United States for 5 years were not more likely to complete treatment when compared to US-born individuals with LTBI (p 0.88). Table 4 lists the various reasons for cessation of therapy for each treatment regimen. More patients receiving 9H discontinued therapy due to complaints of side effects and drug reactions (13 of 213 patients; 6.1%) compared with patients receiving 4R (8 of 261 patients; 3.1%), although the difference was not statistically significant (p 0.12, Fisher exact test). Three cases of drug-induced hepatitis were diagnosed after patients presented with complaints of side effects in the 9H group and no cases in the 4R group. Overall, adverse events requiring cessation of therapy occurred in 21 of 474 patients. In order to see if there was an association between treatment regimen and adverse reaction that might vary by age group, a Cochran-Mantel-Haenszel 2 test was conducted. This test did not identify any significant Table 4 Reason for Treatment Cessation* Reasons 4R (n 261) 9H (n 213) Treatment completed 210 (80.5) 113 (53.1) Patient stopped against advice 10 (3.8) 11 (5.2) Rash/allergy 4 (1.5) 5 (2.4) Headache/flu-like symptoms 3 (1.2) 2 (0.94) Hepatitis 0 3 (1.4) Abdominal discomfort 1 (0.38) 3 (1.41) Unavailable 33 (12.6) 74 (34.7) Diagnosis of active TB 0 1 (0.47) Other medical advice 0 1 (0.47) *Data are presented as No. (% of column). association within each of four age groupings: 24 years, 25 to 34 years, 35 to 44 years, and 45 years (p 0. 06). The major reason for treatment cessation was having the patient be unavailable for follow-up during treatment (n 107; 22.6% overall). Significantly more patients were unavailable in the 9H group (34.7%) compared with the 4R group (12.6%) [p , Fisher exact test]. For the 9H cohort, most patients were unavailable for follow-up between months 1 and 3. For the 4R group, most patients were unavailable after the first month, signifying that there was really no intention to complete therapy after complying with requirements to rule out TB disease. Discussion Using logistic regression analysis, this study showed that a significantly larger proportion of patients receiving the 4R regimen completed LTBI treatment than patients receiving 9H (OR, 5.1; 95% CI, 3.3 to 8.1). The proportion unavailable for follow-up during treatment was nearly three times higher among those receiving 9H compared with those receiving 4R and would likely have been higher had we not allowed those who completed 6 months of INH to be counted as completed. Being employed was negatively associated with treatment completion. This is consistent with our observation that a patient s need to hold on to a job is often more important than keeping an appointment with the Table 3 Logistic Regression Analysis: Treatment Completion Parameters Estimate SE 2 p Value OR Lower 95% CI Upper 95% CI Intercept Employed Foreign born 5 yr vs US born Foreign born 5 yr vs US born Rifampin vs isoniazid CHEST / 130 / 6/ DECEMBER,
5 clinic. None of the demographic factors of the two groups were significant predictors of treatment completion. No significant difference was observed in the occurrence of adverse drug reactions in the two groups. For both regimens, none of the adverse reactions were serious or life threatening, although a smaller proportion of those receiving 4R had drug reactions. The results of this study are consistent with a randomized trial 11 that reported significantly better treatment completion with 4R (86%) compared to 9H (62%), at a significantly lower cost. This study also reported fewer adverse drug reactions in the 4R group, although this was not statistically significant. The principal limitation of our study is that it was not a randomized or blinded trial and that our control group (9H) was from an earlier time period. We recognize that since this was an historical prospective study with historical control subjects, potential unmeasured confounding variables may have affected the results. However, since the treating physician and nurse case manager and nursing staff were the same for both study periods, it is unlikely that the significant differences in completion rates could be ascribed to the caregivers and their management approach. In addition, there were no changes in clinic visit procedures during these time periods. Finally, since the difference in adherence rates were so highly significant, to levels not often if ever seen in self-administered isoniazid therapy for LTBI, we believed that despite the limitations the results were important enough to report now without waiting to conduct a randomized clinical trial. Much of the concern regarding the use of the 4R regimen for treatment of LTBI centers on the paucity of data regarding its efficacy. In an experimental model using mice, Lecoeur and coworkers 12 suggested that 2RZ and 3R were both more effective than 6H. Likewise, the efficacy of rifampin containing preventive chemotherapy (rifampin, rifampinisoniazid, rifampin-pyrazinamide, rifampin-isoniazid-pyrazinamide) was demonstrated by Dhillon et al 13 using Cornell model mice. Only one randomized clinical trial 14 in human subjects directly compared the efficacy of rifampin alone against treatment with isoniazid in the treatment of LTBI in patients with silicosis. The 3 months of rifampin regimen had an efficacy of 63%, compared to 48% for the 6H arm. 14 Other nonrandomized clinical studies 15,16 have suggested the efficacy of rifampin (using a 6-month regimen of rifampin) in preventing TB disease among patients with LTBI who had been exposed to isoniazid-resistant TB cases. Although the American Academy of Pediatrics also recommends 6 months of rifampin in the treatment of children with LTBI who have been exposed to a patient with isoniazidresistant TB, 17 this regimen is not recommended in the current ATS/CDC/IDSA guidelines, 2 and there have been no studies to document the efficacy of this regimen compared with 4R. None of the patients treated during these time periods have been referred back to the clinic to be assessed for development of active disease. A review of the state TB registry is possible and may point to the efficacy of treatment for each group. However, the usefulness of this approach may be limited due to the mobility of the population and the relatively small sample size. A limitation of rifampin for the treatment of LTBI is its potential for drug/drug interactions with drugs such as oral contraceptives, warfarin, and methadone. In our review, most of our patients did not have this problem; but when occasionally encountered, isoniazid was used. The possibility of rifampin staining body fluids, contact lenses, and ocular implants was also discussed with patients. Treatment of LTBI with rifampin is not advised in patients with HIV infection particularly because establishing a diagnosis of TB disease may be sometimes be difficult, increasing the risk for the development of rifampin-resistant disease because of a larger bacterial burden. Additionally, it is well known that rifampin interacts with many antiretrovirals used for HIV. This is an important limitation that could be approached by using isoniazid in any HIV-positive patient starting treatment for LTBI. Risk assessment for HIV infection and counseling for HIV testing should be encouraged. Treatment of LTBI addresses a small bacterial population with monotherapy in order to eliminate them before they multiply and cause TB disease. When starting any patient on treatment with rifampin, as is done for all patients starting treatment for LTBI, the presence of TB disease must be stringently ruled out to avoid the development of drug resistance. The key to treatment of LTBI in any case with any antibiotic is the correct diagnosis. The Tuberculosis Clinical Trials Consortium, funded by the CDC, Department of Health and Human Services is conducting a clinical trial comparing the efficacy of once-weekly directly observed dose of isoniazid and rifapentine for 3 months with that of self-administered 9H for the treatment of LTBI, but it will take several more years to reach a conclusion for this study. Shorter treatments for LTBI are on the distant horizon. However at this point, we believe that the use of 4R should be strongly considered as an important alternative to 9H, particularly in situations in which completion of treatment may be a problem or the likelihood of infection with isoniazid-resistant Mycobacterium tuberculosis is high Original Research
6 Treatment of LTBI is an important component of the US TB-elimination strategy. The results of this study demonstrated a very high level of patient acceptance and adherence with a 4R regimen. 4R is already a recommended alternative regimen to 9H. 2 We believe our data suggest it should be more widely adopted as an alternate treatment regimen for LTBI. ACKNOWLEDGMENT: The authors thank the staff of the Middlesex County, New Jersey tuberculosis clinic, particularly Patty Woods, Marybeth Caruso, and Debbie Apostolis. References 1 Centers for Disease Control and Prevention. Trends in tuberculosis: United States, MMWR Morb Mortal Wkly Rep 2005; 54: American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000; 161:S221 S247 3 Institute of Medicine. Ending neglect: the elimination of tuberculosis in the United States. In: Geiter L, ed. Committee on the Elimination of Tuberculosis in the United States, Division of Health Promotion and Disease Prevention, Institute of Medicine. Washington, DC: National Academy Press, Jordan TJ, Lewitt EM, Montgomery RL, et al. Isoniazid as preventive therapy in HIV infected intravenous drug abusers. JAMA 1991; 265: International Union Against Tuberculosis and Lung Disease. Anti-tuberculosis drug resistance in the world: report No. 3. Geneva, Switzerland: World Health Organization, LoBue P, Moser K. Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med 2003; 168: Dear colleague letter from Dr. Kenneth Castro, Director, Division of Tuberculosis Elimination. Atlanta, GA: Centers for Disease Control and Prevention, Centers for Disease Control and Prevention. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection United States, MMWR Morb Mortal Wkly Rep 2003; 52: Jasmer RM, Nahid P, Hopewell PC. Latent tuberculosis infection. N Engl J Med 2003; 347: Reichman LB, Lardizabal A, Hayden CH. Considering the role of four months of rifampin in the treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2004; 170: Menzies RI, Dion M, Rabinovitch B, et al. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med 2004; 170: Lecoeur HF, Truffot-Pernot C, Grosset JH. Experimental short course chemotherapy with rifampin and pyrazinamide. Am Rev Respir Dis 1989; 140: Dhillon J, Dickinson JM, Sole K, et al. Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampin, isoniazid, and pyrazinamide. Antimicrob Agents Chemother 1996; 40: Hong Kong Chest Service, Tuberculosis Research Centre, Madras, and BMJ Research Council A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis 1992; 145: Polesky A, Farber HW, Gottlieb DJ, et al. Rifampin preventive therapy for tuberculosis in Boston s homeless. Am J Respir Crit Care Med 1996; 154: Villarino M, Ridzon R, Weismuller P, et al. Rifampin preventive therapy for tuberculosis infection. Am J Respir Crit Care Med 1997; 155: American Academy of Pediatrics. Tuberculosis. In: Pickering LK, ed. Red Book: 2003; Report of the Committee on Infectious Diseases, 26th ed. Elk Grove Village, IL: American Academy of Pediatrics, 2003; CHEST / 130 / 6/ DECEMBER,
The Role of Rifampin for the Treatment of Latent TB Infection. Introduction. Introduction
The Role of Rifampin for the Treatment of Latent TB Infection March 26, 2008 Alfred A. Lardizabal, MD Associate Professor of Medicine New Jersey Medical School Global Tuberculosis institute Treatment of
More informationImproved Adherence and Less Toxicity With Rifampin vs Isoniazid for Treatment of Latent Tuberculosis
ORIGINAL INVESTIGATION Improved Adherence and Less Toxicity With Rifampin vs Isoniazid for Treatment of Latent Tuberculosis A Retrospective Study Kathleen R. Page, MD; Frangiscos Sifakis, PhD; Ruben Montes
More informationWeekly. August 8, 2003 / 52(31);
Weekly August 8, 2003 / 52(31);735-739 Update: Adverse Event Data and Revised American Thoracic Society/CDC Recommendations Against the Use of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis
More informationDiagnosis and Medical Management of TB Infection Lisa Y. Armitige, MD, PhD September 12, TB Nurse Case Management September 12 14, 2017
Diagnosis and Medical Management of TB Infection Lisa Y. Armitige, MD, PhD September 12, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has
More informationTherapy for Latent Tuberculosis Infection
Screening and Treatment of LTBI in TB Control in the US Margarita Elsa Villarino MD MPH Division of TB Elimination, CDC April 14, 2004 TB Prevention and Control in the United States The fundamental strategies
More informationExperience with Pyrazinamide and Rifampin Regimens for Latent TB Infection
Experience with Pyrazinamide and Rifampin Regimens for Latent TB Infection Krista Powell, MD, MPH Co-Project Officer, National Surveillance for Severe Adverse Events Associated with LTBI Treatment Lead,
More informationThe Tip of the Iceberg: Addressing Latent Tuberculosis Infection to Accelerate Tuberculosis Elimination
Four Corners TB and HIV Conference November 3, 2015 Durango, CO The Tip of the Iceberg: Addressing Latent Tuberculosis Infection to Accelerate Tuberculosis Elimination Philip LoBue, MD National Center
More informationPlease evaluate this material by clicking here:
EPI Case Study 3: Cross-Sectional, Case-Control, and Cohort Studies Identification of TB Risk Time to Complete Exercise: 60 minutes LEARNING OBJECTIVES At the completion of this module, participants should
More informationLTBI Videos-Treatment
LTBI Videos-Treatment This program is presented by the Global Tuberculosis Institute and is based on recommendations from the Centers for Disease Control and Prevention. This is the third in a series of
More informationLatent tuberculosis infection
EXECUTIVE SUMMARY Latent tuberculosis infection Updated and consolidated guidelines for programmatic management Executive summary Latent tuberculosis infection (LTBI) is defined as a state of persistent
More informationContact Investigation and Prevention in the USA
Contact Investigation and Prevention in the USA George D. McSherry, MD Division of Infectious Disease Penn State Children s Hospital Pediatric Section TB Center of Excellence Rutgers Global Tuberculosis
More informationTreatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015
Treatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015 Tuberculosis Infection Diagnosis and Treatment April 7, 2015 El Paso, TX EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has
More informationEPI Case Study 2: Reliability, Validity, and Tests of Agreement in M. Tuberculosis Screening Time to Complete Exercise: 30 minutes
EPI Case Study 2: Reliability, Validity, and Tests of Agreement in M. Tuberculosis Time to Complete Exercise: 30 minutes LEARNING OBJECTIVES At the completion of this Case Study, participants should be
More informationChapter 1 Overview of Tuberculosis Epidemiology in the United States
Chapter 1 Overview of Tuberculosis Epidemiology in the United States Table of Contents Chapter Objectives.... 1 Progress Toward TB Elimination in the United States... 3 TB Disease Trends in the United
More informationChapter 5 Treatment for Latent Tuberculosis Infection
Chapter 5 Treatment for Latent Tuberculosis Infection Table of Contents Chapter Objectives.... 109 Introduction.... 111 Candidates for the Treatment of LTBI... 112 LTBI Treatment Regimens.... 118 LTBI
More informationLatent Tuberculosis Infection (LTBI) Questions and Answers for Health Care Providers
Latent Tuberculosis Infection (LTBI) Questions and Answers for Health Care Providers Who Should Be Screened for Latent Tuberculosis Infection (LTBI)?... 2 What tests are used to screen for LTBI?... 2 How
More informationTB EPIDEMIOLOGY. Outline. Estimated Global TB Burden, TB epidemiology
TB EPIDEMIOLOGY TB Clinical Intensive Course Curry International Tuberculosis Center September 30, 2015 Varsha Nimbal, MPH Tuberculosis Control Branch California Department of Public Health 1 Outline TB
More informationU.S. Preventive Services Task Force Recommendation Statement: Screening for Latent Tuberculosis Infection (LTBI) in Adults
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention U.S. Preventive Services Task Force Recommendation Statement: Screening for Latent Tuberculosis Infection (LTBI) in Adults Centers
More informationAuthor s response to reviews
Author s response to reviews Title: Treatment Completion for Latent Tuberculosis Infection: A Retrospective Cohort Study Comparing 9 months of Isoniazid, 4 months of Rifampin and 3 months of Isoniazid
More informationLATENT TUBERCULOSIS SCREENING AND TREATMENT:
LATENT TUBERCULOSIS SCREENING AND TREATMENT: TB or not TB Christopher Kwong, MD and William Rifkin, MD Week 14 Educational Objectives: 1. Understand who should be screened for latent TB infection and why
More informationPediatric Tuberculosis in Los Angeles County: An Update
Pediatric Tuberculosis in Los Angeles County: An Update Julie Higashi, MD PhD Director, Tuberculosis Control Program March 2, 2019 0 Pediatricians will be the driving force of TB elimination in California
More informationFrancis F. Fountain, MD; Elizabeth Tolley, PhD; Cary R. Chrisman, PharmD; and Timothy H. Self, PharmD
Isoniazid Hepatotoxicity Associated With Treatment of Latent Tuberculosis Infection* A 7-Year Evaluation From a Public Health Tuberculosis Clinic Francis F. Fountain, MD; Elizabeth Tolley, PhD; Cary R.
More informationLTBI: Who to Test & When to Treat
LTBI: Who to Test & When to Treat TB Intensive May 10 th, 2016 David Horne, MD, MPH Harborview Medical Center University of Washington DISCLOSURES I have no disclosures or conflicts of interest to report
More informationTuberculosis Populations at Risk
Tuberculosis Populations at Risk One-third of the world is infected with TB, an average of one new infection per second Two million people died from tuberculosis in 2010, 1 every 20 seconds TB is the leading
More informationTuberculosis Epidemiology
Tuberculosis Epidemiology TB CLINICAL INTENSIVE COURSE Curry International Tuberculosis Center October 18, 2017 Varsha Hampole, MPH Tuberculosis Control Branch California Department Of Public Health Outline
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Priftin) Reference Number: CP.PMN.05 Effective Date: 07.01.18 Last Review Date: 02.18 Line of Business: Oregon Helath Plan Revision Log See Important Reminder at the end of this policy
More information10/3/2017. Updates in Tuberculosis. Global Tuberculosis, WHO 2015 report. Objectives. Disclosures. I have nothing to disclose
Disclosures Updates in Tuberculosis I have nothing to disclose Chris Keh, MD Assistant Clinical Professor, Division of Infectious Diseases, UCSF TB Controller, TB Prevention and Control Program, Population
More informationRuth Moro M.D., M.P.H. Medical Epidemiologist. CDC, Division of Tuberculosis Elimination Clinical Research Branch Tuberculosis Trials Consortium
Factors Associated with Non-completion of Latent Tuberculosis Infection (LTBI) Treatment: Reasons other than Adverse Events (AE) The TB Trials Consortium PREVENT TB Study 26 Ruth Moro M.D., M.P.H. Medical
More informationTUBERCULOSIS IN HEALTHCARE SETTINGS Diana M. Nilsen, MD, FCCP Director of Medical Affairs, Bureau of Tuberculosis Control New York City Department of
TUBERCULOSIS IN HEALTHCARE SETTINGS Diana M. Nilsen, MD, FCCP Director of Medical Affairs, Bureau of Tuberculosis Control New York City Department of Health and Mental Hygiene TODAY S PRESENTATION Epidemiology
More informationTuberculosis Tools: A Clinical Update
Tuberculosis Tools: A Clinical Update CAPA Conference 2014 JoAnn Deasy, PA-C. MPH, DFAAPA jadeasy@sbcglobal.net Adjunct Faculty Touro PA Program Learning Objectives Outline the pathogenesis of active pulmonary
More informationDrug Interactions Lisa Armitige, MD, PhD November 17, 2010
Substance Abuse and Tuberculosis Oklahoma City, Oklahoma November 17, 2010 Drug Interactions Lisa Armitige, MD, PhD November 17, 2010 Drug Interactions Lisa Y. Armitige, M.D., Ph.D. Medical Consultant
More informationMoving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012
Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012 LTBI and TB Disease Treatment Cara Christ, MD, MS May 8, 2012 Cara Christ, MD, MS has the following disclosures to make: No conflict
More informationJeffrey R. Starke, M.D. has the following disclosures to make:
AAP 2018 Red Book Tuberculosis: IGRAs and Treatment of TB Infection Jeffrey R. Starke, M.D. May 31, 2018 AAP 2018 Red Book Childhood Tuberculosis: IGRAs and Treatment of TB Infection May 31, 2018 WEBINAR
More informationTUBERCULOSIS. Presented By: Public Health Madison & Dane County
TUBERCULOSIS Presented By: Public Health Madison & Dane County What is Tuberculosis? Tuberculosis, or TB, is a disease caused by a bacteria called Mycobacterium tuberculosis. The bacteria can attack any
More informationThe Most Widely Misunderstood Test of All
The Most Widely Misunderstood Test of All Lee B. Reichman, MD, MPH NJMS Global Tuberculosis Institute History of Treatment of Latent Tuberculosis Infection For more than 4 decades, treatment of persons
More information2016 Annual Tuberculosis Report For Fresno County
206 Annual Tuberculosis Report For Fresno County Cases Rate per 00,000 people 206 Tuberculosis Annual Report Fresno County Department of Public Health (FCDPH) Tuberculosis Control Program Tuberculosis
More informationThe American Experience with TB Elimination
Reaching the Goal of TB Elimination by 2035 March 3, 2015 The American Experience with TB Elimination John Jereb, M.D. Medical officer Division of Tuberculosis Elimination National Center for HIV/AIDS,
More informationAnnual Tuberculosis Report Oregon 2007
Annual Tuberculosis Report Oregon 7 Oregon Department of Human Services Public Health Division TB Program April 8 Page 2 Table of Contents Charts Chart 1 TB Incidence in the US and Oregon, 1985-7.. page
More information2014 Annual Report Tuberculosis in Fresno County. Department of Public Health
214 Annual Report Tuberculosis in Fresno County Department of Public Health www.fcdph.org Tuberculosis (TB) is a common communicable disease caused by the bacterium Mycobacterium tuberculosis and occasionally
More information5. HIV-positive individuals treated with INH should receive Pyridoxine (B6) 25 mg daily or 50 mg twice/thrice weekly on the same schedule as INH
V. TB and HIV/AIDS A. Standards of Treatment and Management The majority of TB treatment principles apply to persons with HIV/AIDS who require treatment for TB disease. The following points are either
More informationExpanding Latent Tuberculosis Infection Testing and Treatment to Accelerate Tuberculosis Elimination
IUATLD North American Region Conference February 24, 2017 Vancouver, BC Expanding Latent Tuberculosis Infection Testing and Treatment to Accelerate Tuberculosis Elimination Philip LoBue, MD National Center
More informationThe authors assessed drug susceptibility patterns
Drug Resistance Among Tuberculosis Patients, 1991 and 1992 New York City, CYNTHIA R. DRIVER, RN, MPH THOMAS R. FRIEDEN, MD, MPH ALAN B. BLOCH, MD, MPH IDA M. ONORATO, MD All the authors are with the Division
More informationFundamentals of Tuberculosis (TB)
TB in the United States Fundamentals of Tuberculosis (TB) From 1953 to 1984, reported cases decreased by approximately 5.6% each year From 1985 to 1992, reported cases increased by 20% 25,313 cases reported
More informationDisclosures. Updates in TB for the PCP: Opportunities for Prevention. Objectives PART 1: WHY TEST? 4/14/2016. None
Disclosures Updates in TB for the PCP: Opportunities for Prevention None Pennan Barry, MD, MPH Chief, Surveillance and Epidemiology, California TB Control Branch Assistant Clinical Professor, Division
More informationTB Infection Who is Testing and Treating? TB Control and Elimination: Current Dilemma. Span of TB Control: 2010
TB Infection Who is Testing and Treating? Jennifer Flood, M.D., M.P.H. California Department of Public Health Tuberculosis Control Branch Jennifer.Flood@cdph.ca.gov 1 TB Control and Elimination: Current
More informationMcClintock et al. BMC Infectious Diseases (2017) 17:146 DOI /s * Correspondence: Equal contributors ˆDeceased
McClintock et al. BMC Infectious Diseases (2017) 17:146 DOI 10.1186/s12879-017-2245-8 RESEARCH ARTICLE Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months
More informationTB Clinical Guidelines: Revision Highlights March 2014
TB Clinical Guidelines: Revision Highlights March 2014 AIR TRAVEL & TB CONTROL With respect to non-ambulance air travel of patients diagnosed with or suspected as having active Mycobacterium tuberculosis,
More informationBackground. The global burden of latent M. tuberculosis. More than 2 billion people infected
What s New in Treatment tof LTBI Alfred Lardizabal, MD November 17, 2011 Washington, D.C. Background The global burden of latent M. tuberculosis infection is enormous More than 2 billion people infected
More informationArizona Annual Tuberculosis Surveillance Report
Arizona Annual Tuberculosis Surveillance Report 2014 Table of Contents I. Executive Summary 1 II. Case Rates 3 III. Cases and Case Rates by Race and Ethnicity 4 IV. Cases by Gender 4 V. Cases and Case
More informationDiagnosis and Medical Management of Latent TB Infection
Diagnosis and Medical Management of Latent TB Infection Marsha Majors, RN September 7, 2017 TB Contact Investigation 101 September 6 7, 2017 Little Rock, AR EXCELLENCE EXPERTISE INNOVATION Marsha Majors,
More informationT. Schaberg, K. Rebhan, H. Lode
Eur Respir J, 1996, 9, 2026 2030 DOI: 10.1183/09031936.96.09102026 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1996 European Respiratory Journal ISSN 0903-1936 Risk factors for side-effects
More informationIsoniazid Preventive Therapy (IPT)
Isoniazid Preventive Therapy (IPT) Josefina Cadorna-Carlos, M.D. Professor of Pediatrics U E R M M M C Objectives 1. Define IPT. 2. Discuss the indications for IPT. 3. Present RCT s for IPT (6H vs 9H).
More informationDiagnosis and Treatment of Tuberculosis, 2011
Diagnosis of TB Diagnosis and Treatment of Tuberculosis, 2011 Alfred Lardizabal, MD NJMS Global Tuberculosis Institute Diagnosis of TB, 2011 Diagnosis follows Suspicion When should we Think TB? Who is
More informationDosage and Administration
SIRTURO product information for healthcare providers 2 WARNINGS: An increased risk of death was seen in the SIRTURO (bedaquiline) treatment group (9/79, 11.4%) compared to the placebo treatment group (2/81,
More informationLatent TB Infection (LTBI) Strategies for Detection and Management
Latent TB Infection (LTBI) Strategies for Detection and Management Patrick T. Dowling MD,MPH Professor and Chair Dept of Family Medicine David Geffen School of Medicine at UCLA Pri-Med March 29 2014 Pdowling@mednet.ucla.edu
More informationPlease distribute a copy of this information to each provider in your organization.
HEALTH ADVISORY TO: Physicians and other Healthcare Providers Please distribute a copy of this information to each provider in your organization. Questions regarding this information may be directed to
More informationACTIVE TUBERCULOSIS IN MACOMB COUNTY, A Review of TB Program Data,
ACTIVE TUBERCULOSIS IN MACOMB COUNTY, 1996-2010 A Review of TB Program Data, 1996-2010 Prepared by: Janice M. Chang, MBBS, MPH Division Director, Health Promotion and Disease Control Macomb County Health
More informationGUIDELINES, STATEMENTS & STANDARDS ON TUBERCULOSIS [AS OF FEBRUARY 2005] PART I. GROUPED BY AGENCY/ORGANIZATION
GUIDELINES, STATEMENTS & STANDARDS ON TUBERCULOSIS [AS OF FEBRUARY 2005] PART I. GROUPED BY AGENCY/ORGANIZATION Agency/Organization Name of the Guide/Statement Available at World Health Organization 1
More informationInterferon Gamma Release Assay Testing for Latent Tuberculosis Infection: Physician Guidelines
Interferon Gamma Release Assay Testing for Latent Tuberculosis Infection: Physician Guidelines Historically, Latent Tuberculosis Infection (LTBI) diagnosis was based on risk assessment, chest x-ray (CXR)
More informationTuberculosis Reporting, Waco-McLennan County Public Health District TB Control WMCPHD (254)
Tuberculosis Reporting, Waco-McLennan County Public Health District TB Control WMCPHD (254)-750-5496 Local health care providers, including physicians offices, labs and hospitals, are required by law to
More informationHepatotoxicity in Children Receiving Isoniazid Therapy for Latent Tuberculosis Infection
Original Article Hepatotoxicity in Children Receiving Isoniazid Therapy for Latent Tuberculosis Infection Shiow-Huey Chang, 1 Payam Nahid 2 and Sarah R. Eitzman 3 1 Public Health Department, Santa Clara
More informationLack of Weight Gain and Relapse Risk in a Large Tuberculosis Treatment Trial
AJRCCM Articles in Press. Published on May 18, 2006 as doi:10.1164/rccm.200511-1834oc Lack of Weight Gain and Relapse Risk in a Large Tuberculosis Treatment Trial 1 Awal Khan Ph.D., 1 Timothy R. Sterling
More informationTreatment of Latent Tuberculosis Infection and Its Clinical Efficacy
REVIEW https://doi.org/10.4046/trd.2017.0052 ISSN: 1738-3536(Print)/2005-6184(Online) Tuberc Respir Dis 2018;81:6-12 Treatment of Latent Tuberculosis Infection and Its Clinical Efficacy Hyung Woo Kim,
More informationTuberculosis: Where Are We Now?
Tuberculosis: Where Are We Now? Amee Patrawalla MD MPH Rutgers - NJ Medical School Global TB Institute Rutgers, The State University of New Jersey Learning Objectives Understand the current epidemiologic
More informationSanta Clara County Tuberculosis Screening Requirement for School Entrance Effective June 1, 2014
Guidelines to Revisions to the School Mandate and Requirements 1) What are the tuberculosis (TB) screening requirements for school entrance in Santa Clara County? Students must undergo a TB risk assessment
More informationManagement of Patients with TB Infection Catalina Navarro, RN, BSN April 7, 2015
Management of Patients with TB Infection Catalina Navarro, RN, BSN April 7, 2015 Tuberculosis Infection Diagnosis and Treatment April 7, 2015 El Paso, TX EXCELLENCE EXPERTISE INNOVATION Catalina Navarro,
More informationTB in Corrections Phoenix, Arizona
TB in Corrections Phoenix, Arizona March 24, 2011 Treatment of Latent TB Infection Renuka Khurana MD, MPH March 24, 2011 Renuka Khurana, MD, MPH has the following disclosures to make: No conflict of interests
More informationFor more information, contact
For more information, contact Division of Tuberculosis Elimination National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Coordinating Center for Infectious Diseases Centers for Disease
More informationDirector, University Health Services. Medical Director
March 2011 Issued, Revised, or Reviewed) Approved by: Office of Student Affairs Director, University Health Services Medical Director SUBJECT: SCREENING OF HEALTH SERVICES STAFF FOR TUBERCULOSIS POLICY
More informationTuberculosis and Diabetes Mellitus. Lana Kay Tyer, RN MSN WA State Department of Health TB Nurse Consultant
Tuberculosis and Diabetes Mellitus Lana Kay Tyer, RN MSN WA State Department of Health TB Nurse Consultant Learning Objectives Understand the impact of uncontrolled diabetes mellitus (DM) on TB infection
More informationLatent Tuberculosis Best Practices
Latent Tuberculosis Best Practices Last Updated September 7, 2016 LTBI Demographics in the US o 13million people in the US with LTBI (estimate) o In 2014, approximately 66% of TB cases in the United States
More informationBetween 1995 and 2010, medical consultants for the
SPECIAL ARTICLE Translating Tuberculosis Research into Practice: Collaboration Between Academic Researchers and Public Health Departments in North Carolina David P. Holland, Emily J. Hecker, Ann W. Mosher,
More informationTreatment of latent tuberculosis infection: An update
INVITED REVIEW SERIES: TUBERCULOSIS SERIES EDITORS: WING WAI YEW, GIOVANNI B. MIGLIORI, CHRISTOPH LANGE Treatment of latent tuberculosis infection: An update PHILIP LOBUE 1 AND DICK MENZIES 2 1 Division
More informationThe Clinical Characteristics and Predictors of Treatment Success of Pulmonary Tuberculosis in Homeless Persons at a Public Hospital in Busan
Korean J Fam Med. 2012;33:372-380 http://dx.doi.org/10.4082/kjfm.2012.33.6.372 The Clinical Characteristics and Predictors of Treatment Success of Pulmonary Tuberculosis in Homeless Persons at a Public
More informationDiagnosis and Medical Case Management of Latent TB. Bryan Rock, MD April 27, 2010
TB Nurse Case Management Lisle, Illinois April 27-28, 28 2010 Diagnosis and Medical Case Management of Latent TB Infection Bryan Rock, MD April 27, 2010 DIAGNOSIS AND MANAGEMENT OF LATENT TUBERCULOSIS
More informationDiagnosis & Management of Latent TB Infection
Diagnosis & Management of Latent TB Infection Prof. Ashok Rattan, MD, MAMS, INSA DFG, WHO Lab Director Academics, Industry: Research, Diagnosis, Public Health, Academics Adviser: Laboratory Operations,
More informationTuberculosis in Alameda County, 2009
Tuberculosis in Alameda County, 29 Alameda County Public Health Department Tuberculosis Overview Tuberculosis (TB) is a communicable disease caused by the bacteria Mycobacterium tuberculosis. TB is spread
More informationTB is Global. Latent TB Infection (LTBI) Sharing the Care: Working Together. September 24, 2014
Sharing the Care: Working Together to Meet the Challenge of TB Presented by: Barbara Cole, RN, PHN, MSN Director, Disease Control County of Riverside Department of Public Health Curry International TB
More informationScaling up LTBI Treatment with Short Course Regimens
April 2016 Scaling up LTBI Treatment with Short Course Regimens Carol Dukes Hamilton, MD, MHS Director, Scientific Affairs, FHI 360 Professor of Medicine, Duke University Disclosures past 12 months No
More informationInitiation of treatment for latent tuberculosis infection in the sheltered homeless in Multnomah County, Oregon
Oregon Health & Science University OHSU Digital Commons Scholar Archive July 2009 Initiation of treatment for latent tuberculosis infection in the sheltered homeless in Multnomah County, Oregon Jessica
More informationEvaluation and Management of the Patient with Latent Tuberculosis Infection (LTBI)
Evaluation and Management of the Patient with Latent Tuberculosis Infection (LTBI) CURTIS FOWLER MPT,PA C ASSISTANT CLINICAL PROFESSOR UNIVERSITY OF THE PACIFIC Learning objectives Recognize the appropriate
More informationManagement of Pediatric Tuberculosis in New Jersey
Management of Pediatric Tuberculosis in New Jersey Helen Aguila, MD NJMS Global TB Institute December 15, 2011 This presentation is in part adapted from Pediatric Tuberculosis by Ann Loeffler, MD : Francis
More informationThe cost-effectiveness of screening for latent tuberculosis infection
INT J TUBERC LUNG DIS 4(12):S127 S133 2000 IUATLD The cost-effectiveness of screening for latent tuberculosis infection Z. Taylor Division of Tuberculosis Elimination, Centers for Disease Control and Prevention,
More information*Bamrasnaradura Infectious Diseases Institute, Nonthaburi 11000, Bangkok Hospital, Bangkok, Thailand. ABSTRACT
OriginalArticle Isoniazid Prophylaxis of Latent Tuberculous Infection among Healthcare Workers in Bamrasnaradura Infectious Diseases Institute Patama Suttha, M.D.*, Pranom Noppakun, M.NS.*, Patchara Tanthirapat,
More informationLatent TB Infection Treatment
Latent TB Infection Treatment Douglas B. Hornick, MD Pulmonologist w/ Infectious Attitude Division of Pulmonary/Critical Care/Occ Med UI Carver College of Medicine 2014 MFMER slide-1 Disclosures: None
More informationPrimer on Tuberculosis (TB) in the United States
Primer on Tuberculosis (TB) in the United States The purpose of this primer is to provide instructors who have no prior background in TB research or clinical care with basic knowledge that they may find
More informationInfections What is new and what is important?
Infections What is new and what is important? 2 What am I going to talk about? Imported infections Meningitis changes Flu vaccine issues TB NICE guidance changes 3 Imported infections - Zika Transmitted
More informationDetection and Treatment of Tuberculosis in Correctional Facilities: Opportunities and Challenges
Detection and Treatment of Tuberculosis in Correctional Facilities: Opportunities and Challenges David Karol, MD, MA Bureau of Prisons, FMC Butner Duke University Medical Center June 26, 2013 No Disclosures
More informationImmunization Policy. "UIC/COD-sponsored graduate education program" is one for which UIC/COD maintains academic responsibility.
I. PURPOSE Immunization Policy TITLE: CLINICAL HEALTHCARE PROVIDERS - IMMUNIZATIONS AND HEALTH REQUIREMENTS To prevent or reduce the risk of transmission of vaccine-preventable and other communicable diseases
More informationDecreasing tuberculosis morbidity in the United
Acceptability of Short-Course Rifampin and Pyrazinamide Treatment of Latent Tuberculosis Infection Among Jail Inmates* Naomi N. Bock, MD; Tara Rogers, BS; Jane R. Tapia, RN; George D. Herron, MHA; Beverly
More informationLatent Tuberculosis Infection Reporting Instructions for Civil Surgeons Using CalREDIE Provider Portal
Latent Tuberculosis Infection Reporting Instructions for Civil Surgeons Using CalREDIE Provider Portal Civil surgeons are required to report tuberculosis (TB) screening outcomes that result in latent TB
More information2015 Annual Report Tuberculosis in Fresno County. Department of Public Health
215 Annual Report Tuberculosis in Fresno County Department of Public Health www.fcdph.org Number of Cases Rate per 1, Population 215 Tuberculosis Annual Report Fresno County Department of Public Health
More informationANNUAL TUBERCULOSIS REPORT OREGON Oregon Health Authority Public Health Division TB Program November 2012
ANNUAL TUBERCULOSIS REPORT OREGON 211 Oregon Health Authority Public Health Division TB Program November 212 Page 2 Table of Contents Charts Chart 1 TB Incidence in the US and Oregon, 1985-211... page
More informationTuberculin Testing and Risk of Tuberculosis Infection Among New York City Schoolchildren
Tuberculin Testing and Risk of Tuberculosis Infection Among New York City Schoolchildren Celine R. Gounder, ScM*; Cynthia R. Driver, RN, MPH*; Jerod N. Scholten, MPH*; Huimin Shen, MSPH ; and Sonal S.
More informationPre-Treatment Evaluation. Treatment of Latent TB Infection (LTBI) Initiating Treatment: Patient Education. Before initiating treatment for LTBI:
Pre-Treatment Evaluation Before initiating treatment for LTBI: Treatment of Latent TB Infection (LTBI) Amee Patrawalla, MD Associate Professor, New Jersey Medical School Attending Physician, NJMS Global
More informationTuberculosis Intensive November 17 20, 2015 San Antonio, TX
Treatment of Tuberculosis Elizabeth S. Guy, MD November 17, 2015 Tuberculosis Intensive November 17 20, 2015 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Elizabeth S. Guy, MD has the following disclosures
More informationCommunity pharmacy-based tuberculosis skin testing
Community pharmacy-based tuberculosis skin testing Shanna K. O Connor, PharmD ISU KDHS Spring CE Seminar 2018 In support of improving patient care, Idaho State University Kasiska Division of Health Sciences
More informationA Mobile Health Intervention Utilizing Community Partnership to Improve Access to Latent Tuberculosis Infection Treatment
A Mobile Health Intervention Utilizing Community Partnership to Improve Access to Latent Tuberculosis Infection Treatment Cassandra Garcia, MSN, RN, FNP-BC Mobile Clinic Provider Texas Children s Mobile
More information